Folate receptor-targeted liposomes as possible delivery vehicles for boron neutron capture therapy

Anticancer Res. 2003 Jul-Aug;23(4):3341-5.

Abstract

Background: The folate receptor is amplified in a variety of human tumors including over 90% of ovarian carcinoma. FR-targeted liposomes have previously been used by us to selectively deliver entrapped boron-containing compounds to tumor cells for neutron capture therapy (NCT). In the present study we have evaluated the delivery of Na3(B20H17NH3), which has been loaded into FR-targeted liposomes, in mice bearing xenograft implants of FR (+) KB subcutaneous tumor.

Materials and methods: Na3(B20H17NH3) was passively entrapped into FR-targeted liposomes, which were administered intravenously into nude mice bearing s.c. implants of the FR(+) human oral carcinoma KB cell line. Normal and tumor boron content was measured by direct current plasma-atomic emission spectroscopy.

Results: Mice that received FR-targeted liposomes containing boron showed the highest tumor boron levels at 24 hours (6.1 micrograms/g) and tumor/blood boron ratios continued to rise for up to 120 hours.

Conclusion: Boron delivery via FR-targeted liposomes is feasible and potentially can improve tumor uptake compared to non-targeted liposomes, and may improve cellular and subcellular localization.

MeSH terms

  • Animals
  • Boron Compounds / administration & dosage*
  • Boron Compounds / pharmacokinetics
  • Boron Neutron Capture Therapy / methods*
  • Carrier Proteins / metabolism*
  • Drug Carriers
  • Female
  • Folate Receptors, GPI-Anchored
  • Humans
  • KB Cells
  • Liposomes / administration & dosage
  • Liposomes / metabolism*
  • Liposomes / pharmacokinetics
  • Mice
  • Mice, Nude
  • Receptors, Cell Surface*
  • Tissue Distribution
  • Xenograft Model Antitumor Assays

Substances

  • Boron Compounds
  • Carrier Proteins
  • Drug Carriers
  • Folate Receptors, GPI-Anchored
  • Liposomes
  • Receptors, Cell Surface